✦ LIBER ✦

Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease

✍ Scribed by May, Patrick; Boggs, Leonard; Brier, Richard; Calligaro, David; Citron, Martin; Day, Theresa; Lin, Suizhen; Lindstrom, Terry; Mergott, Dustin; Monk, Scott; Sanchez-Felix, Manuel Vicente; Sheehan, Scott; Vaught, Grant; Yang, Zhixiang; Audia, James

Book ID: 122363676
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 83 KB
Volume: 8
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2012.05.2125

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preclinical characterization of LY288672

Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease

✍ Patrick May; Leonard Boggs; Richard Brier; David Calligaro; Martin Citron; There 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Boom in the development of non-peptidic

Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease

✍ Romano Silvestri 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

## Abstract β‐Amyloid cleaving enzyme‐1 (BACE1) has become a significant target for the therapy of Alzheimer's disease. After the discovery of the first non‐peptidomimetic β‐secretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The non‐

Preclinical and clinical challenges in t

Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease

✍ Carol A Scorer 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 130 KB

ChemInform Abstract: Boom in the Develop

ChemInform Abstract: Boom in the Development of Non-Peptidic β-Secretase (BACE1) Inhibitors for the Treatment of Alzheimer′s Disease

✍ Romano Silvestri 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 16 KB 👁 1 views

Rationale and strategy for thalidomide a

Rationale and strategy for thalidomide as a BACE 1 inhibitor for a phase II randomized clinical trial in mild-to-moderate Alzheimer's disease

✍ Sabbagh, Marwan N.; Nural, Hikmet; He, Ping; Sirrel, Sherye; Belden, Christine; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Preclinical and Phase 1 clinical charact

Preclinical and Phase 1 clinical characterization of CI-979/ RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease

✍ Allen J. Sedman; Howard Bockbrader; Roy D. Schwarz 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 445 KB